Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Minerva Neuroscie (NQ: NERV )

5.970 +0.050 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,342
Open 5.780
Bid (Size) 5.500 (4)
Ask (Size) 6.400 (3)
Prev. Close 5.920
Today's Range 5.620 - 6.070
52wk Range 1.260 - 15.27
Shares Outstanding 5,568,406
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Company to host conference call today at 8:30 a.m. ET 
From Minerva Neurosciences, Inc
Via GlobeNewswire
Earnings Preview For Minerva Neurosciences
 
Via Benzinga

Performance

YTD
+295.36%
+295.36%
1 Month
+58.78%
+58.78%
3 Month
+176.39%
+176.39%
6 Month
+78.74%
+78.74%
1 Year
+86.56%
+86.56%

More News

Read More
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
From Minerva Neurosciences, Inc
Via GlobeNewswire
Minerva Neurosciences Inc. (NASDAQ: NERV) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Earnings Preview For Minerva Neurosciences
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Earnings Scheduled For March 8, 2023
Via Benzinga
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
EXCLUSIVE: The Benzinga Moneymaker Series, 5 Emerging Stocks For Investors To Watch
Via Benzinga
Tesla, Amazon, Minerva, Kala Pharma, Gorilla Tech: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Tumbles 150 Points; Crude Oil Falls Sharply
Via Benzinga
US Stocks Rise; Dow Gains 100 Points
Via Benzinga
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
Via FinancialNewsMedia
Topics Retirement
Exposures Pension Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.